Biotech News

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

UroGen Pharma (URGN)UroGen Pharma2026-06-25 13:46 ESTFinancing

Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt facility and provide additional non-dilutive capital Additional $50 million tranche

Open original release

Related news

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

URGNUroGen Pharma2026-06-25 13:46 EST

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at Upcoming Investor Conferences

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

URGNUroGen Pharma2026-06-25 13:46 EST

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

URGNUroGen Pharma2026-06-25 13:46 EST

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

View all latest news

UroGen Pharma

UroGen Pharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

URGNUroGen Pharma2026-06-26 09:30 EST

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

URGNUroGen Pharma2026-06-26 09:30 EST

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

URGNUroGen Pharma2026-06-26 09:30 EST

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

URGNUroGen Pharma2026-06-26 09:30 EST

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

URGNUroGen Pharma2026-06-26 09:30 EST

UroGen Pharma to Present at Upcoming Investor Conferences

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States